|Shareholder/Beneficial Owner||Shares||% ISC|
|T Rowe Price Global Investments||135,154,175||16.88|
|Canaccord Genuity Wealth Management (Inst)||52,873,228||6.60|
|Hargreaves Lansdown, stockbrokers||49,810,462||6.22|
|Dr Andrew W Nelson*||36,140,417||4.54|
|AXA Framlington Investment Managers||27,580,065||3.44|
|Barclays Smart Investor||24,177,388||3.02|
as at 28 January 2021
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 800,788,829 Ordinary shares
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.8%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: There are currently no IQE plc shares held in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings